On February 25, 2019, Ipsen and Clementia Pharmaceuticals announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals to execute on their external innovation strategy to identify and acquire innovative medicines to serve patients with unmet medical needs. The transaction will boost Ipsen's participation in the treatment of rare diseases and bulk up its pipeline of future treatments.
Morgan Stanley is a leading global financial services firm providing investment banking, securities, investment management and wealth management services to corporations, governments, financial institutions, and individuals.
Clementia Pharmaceuticals, based out of Montreal, is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases.
Osler, Hoskin & Harcourt LLP (Doug Marshall) is representing Morgan Stanley as the exclusive financial advisor to Clementia.
Key Contact
Partner, Corporate, Toronto
